MX2021011501A - Inhibidores de pi4-cinasa y métodos para usar los mismos. - Google Patents
Inhibidores de pi4-cinasa y métodos para usar los mismos.Info
- Publication number
- MX2021011501A MX2021011501A MX2021011501A MX2021011501A MX2021011501A MX 2021011501 A MX2021011501 A MX 2021011501A MX 2021011501 A MX2021011501 A MX 2021011501A MX 2021011501 A MX2021011501 A MX 2021011501A MX 2021011501 A MX2021011501 A MX 2021011501A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- kinase
- treating
- kinase inhibitor
- cancer
- Prior art date
Links
- 102000001556 1-Phosphatidylinositol 4-Kinase Human genes 0.000 title abstract 6
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 4
- 108010029190 1-Phosphatidylinositol 4-Kinase Proteins 0.000 title 1
- 101710115400 Phosphatidylinositol 4-kinase LSB6 Proteins 0.000 abstract 5
- 101710140706 Phosphatidylinositol 4-kinase PIK1 Proteins 0.000 abstract 5
- 101710185028 Phosphatidylinositol 4-kinase stt4 Proteins 0.000 abstract 5
- CNWINRVXAYPOMW-FCNJXWMTSA-N 1-stearoyl-2-arachidonoyl-sn-glycero-3-phospho-1D-myo-inositol 4,5-biphosphate Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(O)(=O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O CNWINRVXAYPOMW-FCNJXWMTSA-N 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 244000052769 pathogen Species 0.000 abstract 3
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000001717 pathogenic effect Effects 0.000 abstract 2
- -1 2-amino-5-pyridylthiazole compound Chemical class 0.000 abstract 1
- LSLUWQIENURREM-UHFFFAOYSA-N 5-phenyl-1,3-thiazol-2-amine Chemical class S1C(N)=NC=C1C1=CC=CC=C1 LSLUWQIENURREM-UHFFFAOYSA-N 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000002924 anti-infective effect Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/48—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962821853P | 2019-03-21 | 2019-03-21 | |
| PCT/US2020/023654 WO2020191205A1 (en) | 2019-03-21 | 2020-03-19 | Pi4-kinase inhibitors and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021011501A true MX2021011501A (es) | 2022-01-18 |
Family
ID=72519365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021011501A MX2021011501A (es) | 2019-03-21 | 2020-03-19 | Inhibidores de pi4-cinasa y métodos para usar los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12415788B2 (https=) |
| EP (1) | EP3941909A4 (https=) |
| JP (2) | JP7701051B2 (https=) |
| KR (1) | KR20220035322A (https=) |
| CN (1) | CN114174275A (https=) |
| AU (2) | AU2020241869B2 (https=) |
| BR (1) | BR112021018724A8 (https=) |
| CA (1) | CA3134417A1 (https=) |
| IL (1) | IL286485B2 (https=) |
| MX (1) | MX2021011501A (https=) |
| WO (1) | WO2020191205A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017147526A1 (en) | 2016-02-26 | 2017-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Pi-kinase inhibitors with anti-infective activity |
| KR20220035322A (ko) * | 2019-03-21 | 2022-03-22 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Pi4-키나아제 억제제 및 이의 사용 방법 |
| EP4676485A1 (en) | 2023-03-09 | 2026-01-14 | Curovir Ab | Compound and formulation for systemic therapy by oral transmucosal administration |
| CN117534631B (zh) * | 2024-01-09 | 2024-04-05 | 南京市鸿舜医药科技有限公司 | 一种苯基噻唑胺类PI4KIIIβ抑制剂、制法及其药物组合物和应用 |
| CN120919132B (zh) * | 2025-10-14 | 2026-01-27 | 中南大学 | Gsk-f1在制备降低nsun2蛋白稳定性、实体肿瘤靶向治疗和/或放疗增敏药物中的应用 |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO115522B1 (ro) | 1995-02-02 | 2000-03-30 | Smithkline Beecham P.L.C. | Derivaţi de indolină, procedee pentru prepararea acestora, compoziţii farmaceutice care îi conţin şi metodă de tratament |
| CN1251671C (zh) | 2000-05-19 | 2006-04-19 | 武田药品工业株式会社 | β分泌酶抑制剂 |
| AUPR738301A0 (en) | 2001-08-30 | 2001-09-20 | Starpharma Limited | Chemotherapeutic agents |
| TWI314928B (en) | 2002-02-28 | 2009-09-21 | Novartis A | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
| US7361669B2 (en) | 2003-01-02 | 2008-04-22 | Millennium Pharmaceuticals, Inc. | Compositions and method for inhibiting TGF-β |
| GB0305152D0 (en) | 2003-03-06 | 2003-04-09 | Novartis Ag | Organic compounds |
| EP1603858A2 (en) | 2003-03-11 | 2005-12-14 | NeuroSearch A/S | Kcnq channel modulating compounds and their pharmaceutical use |
| TW200505902A (en) | 2003-03-20 | 2005-02-16 | Schering Corp | Cannabinoid receptor ligands |
| TW200519106A (en) | 2003-05-02 | 2005-06-16 | Novartis Ag | Organic compounds |
| GB0320197D0 (en) | 2003-08-28 | 2003-10-01 | Novartis Ag | Organic compounds |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| SG155222A1 (en) | 2004-08-13 | 2009-09-30 | Genentech Inc | Thiazole based inhibitors of atp-utilizing enzymes |
| SE0402735D0 (sv) | 2004-11-09 | 2004-11-09 | Astrazeneca Ab | Novel compounds |
| NZ563866A (en) | 2005-05-09 | 2011-03-31 | Achillion Pharmaceuticals Inc | Thiazole compounds and methods of use |
| BRPI0619730A2 (pt) | 2005-12-12 | 2011-10-11 | Genelabs Tech Inc | compostos antivirais de n-(anel aromático de 5 membros)-amido |
| CA2634147A1 (en) | 2005-12-22 | 2007-06-28 | Icagen, Inc. | Calcium channel antagonists |
| AU2007206860A1 (en) | 2006-01-23 | 2007-07-26 | Laboratoires Serono S.A. | Thiazole derivatives and use thereof |
| US20070212717A1 (en) | 2006-02-24 | 2007-09-13 | George Kukolj | Method for Inhibiting Hepatitis C Virus Replication |
| EP2016075A1 (en) | 2006-05-03 | 2009-01-21 | AstraZeneca AB | Thiazole derivatives and their use as anti-tumour agents |
| GB0608823D0 (en) | 2006-05-04 | 2006-06-14 | Chroma Therapeutics Ltd | Inhibitors of P13 kinase |
| WO2008020227A2 (en) | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Antibacterial pyrrolecarboxamides |
| WO2008154601A1 (en) | 2007-06-12 | 2008-12-18 | Genelabs Technologies, Inc. | Anti-viral inhibitors and methods of use |
| WO2009021137A2 (en) | 2007-08-07 | 2009-02-12 | Purdue Research Foundation | Kinase inhibitors and uses thereof |
| AU2008298948B2 (en) | 2007-09-12 | 2014-09-04 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| EP2240475B1 (en) | 2007-12-20 | 2013-09-25 | Novartis AG | Thiazole derivatives used as pi 3 kinase inhibitors |
| US20110262565A1 (en) | 2008-05-29 | 2011-10-27 | Glenn Jeffrey S | PIP-2 Inhibition-Based Antiviral and Anti-Hyperlipidemic Therapies |
| US8106209B2 (en) | 2008-06-06 | 2012-01-31 | Achillion Pharmaceuticals, Inc. | Substituted aminothiazole prodrugs of compounds with anti-HCV activity |
| MX2010013876A (es) | 2008-06-20 | 2011-03-04 | Metabolex Inc | Agonistas de arilo grpr119 y sus usos . |
| DE102008061214A1 (de) | 2008-12-09 | 2010-06-10 | Merck Patent Gmbh | Chinazolinamidderivate |
| JPWO2011007819A1 (ja) | 2009-07-17 | 2012-12-27 | 塩野義製薬株式会社 | ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬 |
| US9926309B2 (en) * | 2011-10-05 | 2018-03-27 | The Board Of Trustees Of The Leland Stanford Junior University | Pi-kinase inhibitors with anti-infective activity |
| US9309236B2 (en) | 2011-10-05 | 2016-04-12 | The Board Of Trustees Of The Leland Stanford Junior University | PI-kinase inhibitors with broad spectrum anti-infective activity |
| CN107007597A (zh) | 2012-05-31 | 2017-08-04 | 菲尼克斯药品股份公司 | 作为孤儿核受体RORγ调节物的经甲酰胺或磺酰胺取代的噻唑及相关衍生物的制药用途 |
| GB201410816D0 (en) | 2014-06-17 | 2014-07-30 | Ucb Biopharma Sprl And Katholieke Universiteit Leuven | Therapeutic agents |
| GB201410817D0 (en) | 2014-06-17 | 2014-07-30 | Ucb Biopharma Sprl And Katholieke Universiteit Leuven K U Leuven R & D | Therapeutic agents |
| WO2016123054A2 (en) | 2015-01-26 | 2016-08-04 | The University Of North Carolina At Chapel Hill | Kinase drug combinations and methods of use thereof |
| CN107949563B (zh) | 2015-06-24 | 2020-06-05 | 库洛维公司 | 治疗中有用的吡唑并[1,5-a]三嗪-4-胺衍生物 |
| CN105326831B (zh) | 2015-11-25 | 2021-01-29 | 中国科学院生物物理研究所 | 肌醇磷脂4位激酶二型α亚型特异抑制剂PI-273的应用 |
| WO2017147526A1 (en) * | 2016-02-26 | 2017-08-31 | The Board Of Trustees Of The Leland Stanford Junior University | Pi-kinase inhibitors with anti-infective activity |
| US20190358196A1 (en) * | 2016-07-27 | 2019-11-28 | Henry C. Lowe | Pi 4-kinase inhibitor as a therapeutic for viral hepatitis, cancer, malaria. autoimmune disorders and inflammation, and a radiosensitizer and immunosuppressant |
| WO2018029126A1 (en) | 2016-08-08 | 2018-02-15 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| DK3606926T3 (da) | 2017-04-05 | 2021-07-05 | Curovir Ab | Heteroaromatiske forbindelser anvendelige i terapi |
| CA3126143A1 (en) | 2019-01-11 | 2020-07-16 | The Board Of Trustees Of The Leland Stanford Junior University | Pi4-kinase inhibitors with anti-cancer activity |
| KR20220035322A (ko) * | 2019-03-21 | 2022-03-22 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | Pi4-키나아제 억제제 및 이의 사용 방법 |
-
2020
- 2020-03-19 KR KR1020217033963A patent/KR20220035322A/ko not_active Ceased
- 2020-03-19 IL IL286485A patent/IL286485B2/en unknown
- 2020-03-19 AU AU2020241869A patent/AU2020241869B2/en active Active
- 2020-03-19 JP JP2021556906A patent/JP7701051B2/ja active Active
- 2020-03-19 CA CA3134417A patent/CA3134417A1/en active Pending
- 2020-03-19 EP EP20774679.3A patent/EP3941909A4/en active Pending
- 2020-03-19 WO PCT/US2020/023654 patent/WO2020191205A1/en not_active Ceased
- 2020-03-19 US US17/439,085 patent/US12415788B2/en active Active
- 2020-03-19 BR BR112021018724A patent/BR112021018724A8/pt unknown
- 2020-03-19 MX MX2021011501A patent/MX2021011501A/es unknown
- 2020-03-19 CN CN202080037774.5A patent/CN114174275A/zh active Pending
-
2025
- 2025-05-06 AU AU2025203241A patent/AU2025203241A1/en active Pending
- 2025-06-12 JP JP2025098891A patent/JP2025128323A/ja active Pending
- 2025-07-01 US US19/257,262 patent/US20250326725A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL286485B1 (en) | 2025-05-01 |
| JP7701051B2 (ja) | 2025-07-01 |
| IL286485B2 (en) | 2025-09-01 |
| WO2020191205A1 (en) | 2020-09-24 |
| TW202102479A (zh) | 2021-01-16 |
| AU2025203241A1 (en) | 2025-05-29 |
| IL286485A (en) | 2021-12-01 |
| US20250326725A1 (en) | 2025-10-23 |
| JP2025128323A (ja) | 2025-09-02 |
| EP3941909A1 (en) | 2022-01-26 |
| CA3134417A1 (en) | 2020-09-24 |
| BR112021018724A2 (https=) | 2021-11-23 |
| AU2020241869B2 (en) | 2025-02-13 |
| EP3941909A4 (en) | 2023-01-25 |
| AU2020241869A1 (en) | 2021-11-18 |
| JP2022527255A (ja) | 2022-06-01 |
| BR112021018724A8 (pt) | 2021-11-23 |
| US20220153711A1 (en) | 2022-05-19 |
| US12415788B2 (en) | 2025-09-16 |
| KR20220035322A (ko) | 2022-03-22 |
| CN114174275A (zh) | 2022-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021011501A (es) | Inhibidores de pi4-cinasa y métodos para usar los mismos. | |
| MX2022015272A (es) | Inhibidores de la proteina kras g12c y usos de estos. | |
| MX2021007179A (es) | Pirazolopirimidinas sustituidas y purinas sustituidas y su uso como inhibidores de proteasa procesadora especifica de ubiquitina 1 (usp1). | |
| ECSP20069416A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| CR20240120A (es) | Compuesto inductor de la degradación de PLK1 novedoso | |
| MX2021009276A (es) | Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidora sobre cdk2. | |
| CL2019002056A1 (es) | Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650) | |
| ECSP18005828A (es) | Inhibidores de metalo-beta-lactamasa | |
| MX2018002889A (es) | Compuesto de pirimidina fusionada o sal del mismo. | |
| CL2021002966A1 (es) | Combinación de inhibidores de pd-1 e inhibidores de lag-3 para mejorar la eficacia en el tratamiento del cancer. | |
| BR112015028879A2 (pt) | derivados heterocíclicos | |
| CL2020001752A1 (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa. | |
| BR112017010882B8 (pt) | Compostos de n-((het)-arilmetil)-heteroaril-carboxamidas como inibidores de calicreína plasmática e seus usos | |
| EA201490396A1 (ru) | Ингибиторы репликации вирусов гриппа | |
| JO3121B1 (ar) | مشتقات 1 - ((5-هيتيرورلثيازول-2-يل) أمينوكاربونيل) بيروليدين-2-كربوكساميد كمثبات الفوسفاتديلينوسيتول 3-كيناس (pi3k) مفيدة في علاج الأمراض التصاعدية | |
| CL2022000214A1 (es) | Inhibidores de enzimas | |
| MX2022001004A (es) | Inhibidores de enzimas. | |
| BR112022001054A2 (pt) | Inibidores enzimáticos | |
| MX2020010697A (es) | Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil. | |
| MX2019014411A (es) | Compuestos que contienen nitrogeno sustituido. | |
| CO2022000270A2 (es) | Inhibidores de enzimas | |
| ZA202006612B (en) | Antibacterial compounds | |
| BR112022000936A2 (pt) | Inibidores de enzimas | |
| MX2022006424A (es) | Analogos de equinocandina y metodo de preparacion de los mismos. | |
| MX2023009677A (es) | Inhibidores de enzimas. |